mTORC2 is required for proliferation and survival of TSC2-null cells. - Wikidata - wikimedia - TriplyDB

mTORC2 is required for proliferation and survival of TSC2-null cells.

mTORC2 is required for proliferation and survival of TSC2-null cells.

http://www.wikidata.org/entity/Q34177457

about

mTOR Regulation of Lymphoid Cells in Immunity to Pathogens Optimizing treatments for lymphangioleiomyomatosis Response and acquired resistance to everolimus in anaplastic thyroid cancer Management of lymphangioleiomyomatosis Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK.mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage Multi-parametric profiling network based on gene expression and phenotype data: a novel approach to developmental neurotoxicity testing.Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion.Mammalian target of rapamycin complex 2 signaling pathway regulates transient receptor potential cation channel 6 in podocytes.Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models.Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension.Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.TSC2 modulates cell adhesion and migration via integrin-α1β1 Lymphangioleiomyomatosis - a wolf in sheep's clothing.Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Differential effects of formoterol on thrombin- and PDGF-induced proliferation of human pulmonary arterial vascular smooth muscle cells.Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells.Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.Increased mammalian target of rapamycin complex 2 signaling promotes age-related decline in CD4 T cell signaling and function Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling.The Paradox of Akt-mTOR Interactions.The role of mTORC1 in regulating protein synthesis and skeletal muscle mass in response to various mechanical stimuli.Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.Signaling crosstalk between the mTOR complexes.RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons.A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.

P2860

Q26744649-CEA6B7CE-CAFD-4CF9-A8B5-D55FD2128910 Q26865250-700E62B3-FD9C-4B49-A0C7-1C1B12745544 Q27853080-0A2F653B-68B1-4377-93EC-A9DEACBBAA4D Q28084725-AA5AF260-E516-4510-AFC7-CACDC7A312C9 Q28084975-D8F79897-7200-457D-A33C-7C8A323C800C Q28506632-9624670D-E413-4775-B9D4-678261BC53B6 Q30540707-626FFE3A-DE18-407B-9A5E-8BC17D0C6593 Q30578909-AAC3A641-80BC-4082-9F31-4ED1B70697A2 Q33919744-87679657-77B7-4FB3-9F46-50A252E243BC Q34039918-85A71489-B881-4C64-B13C-3E39C51CB16E Q34152533-D548F3FF-1327-4894-81D5-7D95AC10C5A3 Q34471857-5D34E2B1-70B9-4182-A57F-EA457837045F Q34506500-990F0B66-2BBC-4585-8DE3-5FF1C9820EAE Q34612111-494611BC-CD4B-425E-BCF9-71EFD05ED8C9 Q34840298-14565920-733B-4B55-9E95-F07389E371A7 Q34924914-0B7E7F54-394F-42B4-BAF0-C154417C9E96 Q35381119-1706D3DA-A428-4D86-B340-5D75E0250AF4 Q35676912-44BB0AEB-3343-40CC-883E-B830B3AA1A1C Q36022483-A619AB35-6550-4948-8933-F21CB03D7213 Q36232850-6F47FE91-A794-43E7-8260-ABF04A2BC81C Q36312486-25BA8284-A5B9-4B60-8AD3-3D07D11091C6 Q36357766-E2515B51-0B42-428C-8459-8886D32BC485 Q36382124-A07A163C-900A-4D61-AF47-61988B23CB99 Q36462100-80CC1E34-8087-407A-80EE-A932434C201C Q36535586-6671F3C3-3F30-437A-9B89-0E720410DDBE Q36636671-69F8A3A8-5DC6-4D37-93AB-9A672C686F75 Q36760689-C36D0DD6-C1AC-47AE-A416-5DE3CC93DDBD Q37056468-FFEBD92E-A6E8-47BC-B6A3-5B2E85C1A034 Q37307472-7450F95B-8E9C-494B-A46C-088DF2B71DE8 Q37596461-A398E771-136C-4761-891C-D05C6348B18C Q37670612-608F92D9-4AE6-463C-B290-323A16D0013E Q37937344-509AA5F3-9568-4A55-BB43-65D5708339B3 Q38017247-F98B7BE0-3470-4A02-9CF1-961E7293B332 Q38117148-57F67D95-A460-4784-88A1-9A524AAD5F54 Q38179978-5A03B9A8-067D-4C7F-83AD-A11E9735C802 Q38452625-BC7A7168-1BCE-44B1-B0AB-4996B584462E Q38700659-50A8276C-D797-4EE6-BEFC-B9462A3EF723 Q38836377-E081C1E0-D525-4A56-A870-55A5B98BB4EB Q38841393-F7D83D98-E842-47F0-B350-E1809150F88A Q39372532-BBD310A7-59B8-4992-97DC-17C65C5D8DD8

P2860

mTORC2 is required for proliferation and survival of TSC2-null cells.

http://www.wikidata.org/entity/Q34177457

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

mTORC2 is required for proliferation and survival of TSC2-null cells.

@ast

mTORC2 is required for proliferation and survival of TSC2-null cells.

@en

mTORC2 is required for proliferation and survival of TSC2-null cells.

@nl

type

label

mTORC2 is required for proliferation and survival of TSC2-null cells.

@ast

mTORC2 is required for proliferation and survival of TSC2-null cells.

@en

mTORC2 is required for proliferation and survival of TSC2-null cells.

@nl

prefLabel

mTORC2 is required for proliferation and survival of TSC2-null cells.

@ast

mTORC2 is required for proliferation and survival of TSC2-null cells.

@en

mTORC2 is required for proliferation and survival of TSC2-null cells.

@nl

P1433

Q34177457-4A49E2F4-0564-4282-B268-E9D1DBB31B65

P1476

Q34177457-91C83E3E-9A26-4E53-B766-87DAD458966D

P2093

Q34177457-4B1CA7F7-1665-43DB-A744-817DF3939393

Q34177457-4E02E19F-0395-448E-8353-BBD13853C097

Q34177457-9DA5A8F0-9752-4F02-830C-B24E6711B089

Q34177457-A867594E-9C86-4BFC-88B6-3B7C83BE7CAF

Q34177457-C13550EA-E92C-482E-A828-38F0EE1D9085

Q34177457-DB87121F-8773-4FBC-8DB0-2317A9B52967

Q34177457-ED2700B0-7178-4AAB-807E-BA0AC94F3225

P2860

Q34177457-017D776B-CF74-4FF3-AFEC-121CD9600145

Q34177457-042CC27A-BD98-4CE2-80C2-C90187CA5472

Q34177457-0C52E3B3-B248-420A-BE60-66865E3AF5C4

Q34177457-0ED44228-0CCC-4AAB-A651-011DC7BF7DCB

Q34177457-0F0403D5-9D20-4DB5-ADD4-B916DDC290B5

Q34177457-0F56B50F-4836-4F21-AA2E-E8EF3B2EA428

Q34177457-1289138C-3D76-478D-BB46-03EDC25A4117

Q34177457-133A1A8C-5909-4206-BEC6-432B313B6929

Q34177457-142D3F39-DC9F-4283-9C37-539CDC5D26A1

Q34177457-17B97C0A-330B-43F6-973D-33A283AEBD1E

P304

Q34177457-9567BCF9-D05C-4B62-9925-70ACAD58AC93

P31

Q34177457-34E72F3D-C754-4EB1-9C97-62A97AEB6D9A

P356

Q34177457-14BED5E8-D898-4729-BD75-3CC627F04B4C

P407

Q34177457-DA55BBA2-51FB-47DD-9834-A9D96B35AB3C

P433

Q34177457-F8C13AD1-41D5-4F41-A422-C41CCE4515D3

P478

Q34177457-55502247-7A5A-4FC1-96D9-D417592005B9

P577

Q34177457-26911D1F-6679-4334-B42A-570B54FFF5C6

P698

Q34177457-91561ED1-D333-4738-B52B-65AE4CE5C394

P932

Q34177457-0F767012-7DA3-4CB0-9D9A-7F2F71ECBAF0

P356

P1433

Molecular and Cellular Biology

P1476

mTORC2 is required for proliferation and survival of TSC2-null cells.

@en

P2093

Dmitry A Goncharov

http://www.w3.org/2001/XMLSchema#string

Elena A Goncharova

http://www.w3.org/2001/XMLSchema#string

Hua Li

http://www.w3.org/2001/XMLSchema#string

Irene Khavin

http://www.w3.org/2001/XMLSchema#string

Stephen Lu

http://www.w3.org/2001/XMLSchema#string

Vera P Krymskaya

http://www.w3.org/2001/XMLSchema#string

Wittaya Pimtong

http://www.w3.org/2001/XMLSchema#string

P2860

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony

Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members

Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

Rho GTPases: biochemistry and biology

Rho GTPases in cell biology

P304

2484-2498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/MCB.01061-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21482669

http://www.w3.org/2001/XMLSchema#string

P932

3133430

http://www.w3.org/2001/XMLSchema#string